AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18537503 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke group
Number of subjects: 0
Study 14960504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 mg/day)
Number of subjects: 4912
Study 14960504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4912
Study 11772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Down Tilt
Number of subjects: 32
Study 11772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-Up
Number of subjects: 32
Study 11772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Leg-Up and Head-Down Tilt
Number of subjects: 32
Study 11772833 — intervention group
Group type: COMPARATOR
Intervention: Supine
Number of subjects: 32
Study 9620902 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive load of 3 cm H2O/L/s
Number of subjects: 18
Study 9620902 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive load of 6 cm H2O/L/s
Number of subjects: 18
Study 9620902 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive loads of 3 and 6 cm H2O/L/s
Number of subjects: 18
Study 7866912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate (TP)
Number of subjects: 24
Study 7866912 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 24
Study 2523099 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 51
Study 2523099 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 51
Study 28939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultopride
Number of subjects: 50
Study 28939 — intervention group
Group type: COMPARATOR
Intervention: Fluanisone
Number of subjects: 50
Study 31858116 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC
Number of subjects: 360
Study 31858116 — intervention group
Group type: EXPERIMENTAL
Intervention: JENVAC/JENVAC
Number of subjects: 360
Study 31858116 — intervention group
Group type: COMPARATOR
Intervention: SA 14-14-2
Number of subjects: 360
Study 31858116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 360
Study 31600006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power (HP) radiofrequency application at 50W anterior, 40W posterior, and 30W on the esophagus
Number of subjects: 60
Study 31600006 — intervention group
Group type: COMPARATOR
Intervention: Medium-power (MP) radiofrequency application at 40W anterior and 30W posterior
Number of subjects: 60
Study 31600006 — intervention group
Group type: COMPARATOR
Intervention: Low-power (LP) radiofrequency application at 30W anterior and 20W posterior
Number of subjects: 60
Study 29246257 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention plus multidisciplinary intervention
Number of subjects: 0
Study 29246257 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 0
Study 26667662 — intervention group
Group type: EXPERIMENTAL
Intervention: hFSH stimulation
Number of subjects: 221
Study 26667662 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH stimulation
Number of subjects: 221
Study 26667662 — intervention group
Group type: EXPERIMENTAL
Intervention: hFSH and rFSH
Number of subjects: 221
Study 26667662 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH and FSH levels
Number of subjects: 221
Study 23761206 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Training (internet‐based)
Number of subjects: 599
Study 23761206 — intervention group
Group type: COMPARATOR
Intervention: Group fitness ('Face‐to‐Face')
Number of subjects: 599
Study 23761206 — intervention group
Group type: COMPARATOR
Intervention: Individually supervised training ('Face‐to‐Face')
Number of subjects: 599
Study 23761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program (Face‐to‐Face and e‐Training)
Number of subjects: 599
Study 23761206 — intervention group
Group type: COMPARATOR
Intervention: Group fitness intervention (Study 1)
Number of subjects: 599
Study 23761206 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Training (Study 2)
Number of subjects: 599
Study 21792072 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 9
Study 21792072 — intervention group
Group type: COMPARATOR
Intervention: Conventional strength training (CST)
Number of subjects: 9
Study 19098860 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 100 microg/day
Number of subjects: 42
Study 19098860 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 1,000 microg/day
Number of subjects: 42
Study 19098860 — intervention group
Group type: COMPARATOR
Intervention: linaclotide (100, 300, or 1,000 microg)
Number of subjects: 42
Study 19098860 — intervention group
Group type: COMPARATOR
Intervention: linaclotide
Number of subjects: 42
Study 16808989 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine supplementation (20mg/kg/day)
Number of subjects: 29
Study 16808989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15298560 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized house dust mite immunotherapy (SIT)
Number of subjects: 12
Study 15298560 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 12
Study 11358645 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+simvastatin (10 mg/day)
Number of subjects: 30
Study 11358645 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+bezafibrate (400 mg/day)
Number of subjects: 30
Study 11358645 — intervention group
Group type: COMPARATOR
Intervention: HRT only (control group)
Number of subjects: 30
Study 10225747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) apheresis
Number of subjects: 0
Study 10225747 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 0
Study 11548225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate 500 mg t.i.d.
Number of subjects: 200
Study 11548225 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg t.i.d.
Number of subjects: 200
Study 11548225 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200
Study 3324330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressings
Number of subjects: 41
Study 3324330 — intervention group
Group type: COMPARATOR
Intervention: Dry gauze dressings
Number of subjects: 41
Study 30192326 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal with prazosin 1 mg oral 6 hours before removal
Number of subjects: 142
Study 30192326 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter removal
Number of subjects: 142
Study 30192326 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal
Number of subjects: 142
Study 27888990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg 3 times/day)
Number of subjects: 410
Study 27888990 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (40 mg/day)
Number of subjects: 410
Study 24948549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cappella Sideguard (CS) sidebranch stent
Number of subjects: 52
Study 24948549 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable drug-eluting stents (DES)
Number of subjects: 52
Study 23910429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive target-based medical treatment for cardiac risk factors
Number of subjects: 1750
Study 23910429 — intervention group
Group type: EXPERIMENTAL
Intervention: Better risk factor control during the trial
Number of subjects: 1750
Study 21092089 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 180
Study 21092089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 18208607 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured family meetings (4 sessions)
Number of subjects: 0
Study 18208607 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16340193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Clinic Regimen (MCR) + LV5FU2 (group A)
Number of subjects: 193
Study 16340193 — intervention group
Group type: EXPERIMENTAL
Intervention: MCR + irinotecan (350 mg/m(2)) (group B)
Number of subjects: 193
Study 16340193 — intervention group
Group type: EXPERIMENTAL
Intervention: MCR + FOLFIRI (group C)
Number of subjects: 193
Study 16340193 — intervention group
Group type: EXPERIMENTAL
Intervention: MCR + FOLFOX4 (group D)
Number of subjects: 193
Study 16340193 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + FOLFOX4 (group E)
Number of subjects: 193
Study 14639777 — intervention group
Group type: EXPERIMENTAL
Intervention: AMMA treatments
Number of subjects: 24
Study 14639777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 11128883 — intervention group
Group type: EXPERIMENTAL
Intervention: Filler task
Number of subjects: 258
Study 11128883 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm month
Number of subjects: 258
Study 11128883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuesday
Number of subjects: 258
Study 11128883 — intervention group
Group type: EXPERIMENTAL
Intervention: Credit day
Number of subjects: 258
Study 11128883 — intervention group
Group type: EXPERIMENTAL
Intervention: Time period (1992-1996)
Number of subjects: 258
Study 11128883 — intervention group
Group type: COMPARATOR
Intervention: Task type
Number of subjects: 258
Study 11128883 — intervention group
Group type: COMPARATOR
Intervention: Timing factors
Number of subjects: 258
Study 8945029 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR with SMARTracking (DDDRSM)
Number of subjects: 7
Study 8945029 — intervention group
Group type: COMPARATOR
Intervention: DDDR with Conditional Ventricular Tracking Limit (DDDRC)
Number of subjects: 7
Study 8945029 — intervention group
Group type: COMPARATOR
Intervention: DDDR with standard upper rate behavior
Number of subjects: 7
Study 8945029 — intervention group
Group type: COMPARATOR
Intervention: VVIR
Number of subjects: 7
Study 8945029 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDRSM
Number of subjects: 7
Study 8945029 — intervention group
Group type: COMPARATOR
Intervention: DDDRC
Number of subjects: 7
Study 8945029 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDRSM and DDDRC
Number of subjects: 7
Study 1615136 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg sodium pentobarbital (SIN)
Number of subjects: 12
Study 1615136 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg sodium pentobarbital in divided doses (DIV)
Number of subjects: 12
Study 1615136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3519416 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine (30 mg)
Number of subjects: 10
Study 3519416 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 10
Study 29652768 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage palatoplasty (Group A)
Number of subjects: 100
Study 29652768 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage palatoplasty (Group B)
Number of subjects: 100
Study 29652768 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 100
Study 27716165 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction Disposable (LTS‐D)
Number of subjects: 80
Study 27716165 — intervention group
Group type: COMPARATOR
Intervention: Supreme Laryngeal Mask Airway (SLMA)
Number of subjects: 80
Study 24229434 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simple prostatectomy (LSP)
Number of subjects: 90
Study 24229434 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 90
Study 22210087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpersistent patients aged <65 years
Number of subjects: 3142
Study 22210087 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent patients aged 65-74 years
Number of subjects: 3142
Study 22210087 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent patients aged ≥75 years
Number of subjects: 3142
Study 22210087 — intervention group
Group type: COMPARATOR
Intervention: Nonpersistent patients aged 65-74 years
Number of subjects: 3142
Study 22210087 — intervention group
Group type: COMPARATOR
Intervention: Nonpersistent patients aged ≥75 years
Number of subjects: 3142
Study 20155842 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 42
Study 20155842 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 42
Study 20155842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18716168 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich dark chocolate (FRDC) at 100 g/d for 15 days
Number of subjects: 19
Study 18435368 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT Statement adherence
Number of subjects: 0
Study 18435368 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15507173 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary sentinel node biopsy
Number of subjects: 707
Study 15507173 — intervention group
Group type: COMPARATOR
Intervention: Standard axillary treatment
Number of subjects: 707
Study 11402408 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour drain clamping
Number of subjects: 44
Study 11402408 — intervention group
Group type: COMPARATOR
Intervention: 24-hour drain clamping
Number of subjects: 44
Study 9003262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheobronchial cytology in patients with inhalation injury
Number of subjects: 40
Study 9003262 — intervention group
Group type: COMPARATOR
Intervention: Control patients (no inhalation injury)
Number of subjects: 40
Study 9003262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheobronchial cytology
Number of subjects: 40
Study 8236193 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 44
Study 8236193 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 3122528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk laxatives containing stimulant type laxative
Number of subjects: 59
Study 3122528 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide
Number of subjects: 59
Study 30947293 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV negative women
Number of subjects: 1151
Study 30947293 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 infected women
Number of subjects: 1151
Study 30947293 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed HIV-1 infected women
Number of subjects: 1151
Study 30947293 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with friends/in a house-share (among HIV positive women)
Number of subjects: 1151
Study 30947293 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending antenatal care (ANC) for the most recent pregnancy (among HIV positive women)
Number of subjects: 1151
Study 30947293 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with friends/in a house-share (among HIV negative women)
Number of subjects: 1151
Study 27038240 — intervention group
Group type: EXPERIMENTAL
Intervention: Redemption Reintegration Services (RRS)
Number of subjects: 115
Study 27038240 — intervention group
Group type: COMPARATOR
Intervention: Usual reintegration services
Number of subjects: 115
Study 24652899 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH II intervention
Number of subjects: 494
Study 24652899 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention
Number of subjects: 494
Study 23994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 404
Study 23994107 — intervention group
Group type: COMPARATOR
Intervention: Neo-adjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS)
Number of subjects: 404
Study 23994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 404
Study 23994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutions with good QOL compliance
Number of subjects: 404
Study 23994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 404
Study 23994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression free survival
Number of subjects: 404
Study 21947389 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-Q2 (250 mg, twice a day)
Number of subjects: 161
Study 21947389 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg, twice a day)
Number of subjects: 161
Study 21947389 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-Q2
Number of subjects: 161
Study 21947389 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 161
Study 21947389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea and vomiting
Number of subjects: 161
Study 19846653 — intervention group
Group type: EXPERIMENTAL
Intervention: pvl-positive MRSA
Number of subjects: 522
Study 19846653 — intervention group
Group type: COMPARATOR
Intervention: pvl-negative MRSA
Number of subjects: 522
Study 16756534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy infant formula (1 kcal mL(‐1)) at full strength from day 1
Number of subjects: 30
Study 16756534 — intervention group
Group type: COMPARATOR
Intervention: Diluted high-energy infant formula, graded to full strength over 3 days
Number of subjects: 30
Study 15361886 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (16 mg OD)
Number of subjects: 13
Study 15361886 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg OD)
Number of subjects: 13
Study 15361886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11524054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu23F2G (low-dose 0.3 mg/kg)
Number of subjects: 60
Study 11524054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu23F2G (high-dose 1.0 mg/kg)
Number of subjects: 60
Study 11524054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11524054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu23F2G (low-dose and high-dose)
Number of subjects: 60
Study 9259500 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Lithium Succinate cream (8% lithium succinate, 0.05% zinc sulphate)
Number of subjects: 101
Study 9259500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8518572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 600
Study 8518572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 3102711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin therapy (0.5 g/kg/wk for 1 month in group 1 and during intensive care in group 2)
Number of subjects: 133
Study 3102711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin therapy
Number of subjects: 133
Study 3102711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gammaglobulin therapy)
Number of subjects: 133
Study 29730330 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based aerobic training (WA)
Number of subjects: 69
Study 29730330 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based resistance training (WR)
Number of subjects: 69
Study 29730330 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 69
Study 26962509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600 IU/day)
Number of subjects: 140
Study 26962509 — intervention group
Group type: COMPARATOR
Intervention: Control group (supplementation free of vitamin D)
Number of subjects: 140
Study 23532629 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (Epo-b) 30000 IU once weekly, increased to 30000 IU twice weekly if Hb increase was <0.5 g/dl after 4 weeks
Number of subjects: 118
Study 23532629 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (Epo-b)
Number of subjects: 118
Study 23532629 — intervention group
Group type: COMPARATOR
Intervention: Control group (irinotecan or cisplatin without Epo-b)
Number of subjects: 118
Study 22318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure hemorrhoidectomy (LH)
Number of subjects: 98
Study 22318061 — intervention group
Group type: COMPARATOR
Intervention: Stapled hemorrhoidectomy (SH)
Number of subjects: 98
Study 22318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 98
Study 20875231 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Tenofovir (TFV) + 200 mg Emtricitabine (FTC) + 300 mg Lamivudine (3TC) tablet formulation
Number of subjects: 43
Study 18603377 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Sedation (PCS) with propofol/alfentanil
Number of subjects: 11
Study 18603377 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist Controlled Sedation (ACS)
Number of subjects: 11
Study 18603377 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Sedation (PCS)
Number of subjects: 11
Study 15818478 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-inversion harmonic imaging (PIHI)
Number of subjects: 41
Study 15818478 — intervention group
Group type: COMPARATOR
Intervention: Conventional B-mode ultrasound (US)
Number of subjects: 41
Study 11594641 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training on a treadmill with body weight support (BWS) for 30 minutes, 5 days a week
Number of subjects: 73
Study 11594641 — intervention group
Group type: COMPARATOR
Intervention: Walking training on the ground according to the Motor Relearning Programme (MRP) for 30 minutes, 5 days a week
Number of subjects: 73
Study 9641613 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ subjects
Number of subjects: 14
Study 9641613 — intervention group
Group type: COMPARATOR
Intervention: HIV- subjects
Number of subjects: 14
Study 8039850 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 131
Study 8039850 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 131
Study 2647025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 26
Study 2647025 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 26
Study 29771567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eating ritual over a 5-day period
Number of subjects: 6
Study 29771567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairing a ritual with healthy eating behavior
Number of subjects: 6